All In Biotech

Drug Trial Radar · NCT05951179

Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer

A Phase 2, Open-Label Study to Evaluate the Safety and Efficacy of Intravesical Instillation of TARA-002 in Adults With High-Grade Non-Muscle Invasive Bladder Cancer

Last checked: Nov 19, 2026Latest source record: Aug 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

131

Planned (sponsor's estimate)

Start

Sep 15, 2023

Primary completion

Oct 2031

Study completion Mar 2032

Sponsor

Lead sponsor
Protara TherapeuticsIndustry
Sponsor type
Industry
First posted
Jul 18, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

TARA-002-101-Ph2 is an open-label study to investigate the safety and efficacy of intravesical instillation of TARA-002 in adults 18 years of age or older with high-grade CIS NMIBC (± Ta/T1). The purpose of this Phase 2 study (TARA-002-101-Ph2) is to further assess the safety and efficacy of TARA-002 at the RP2D which has been established in the Phase 1a dose finding study (TARA-002-101-Ph1a). This Phase 2 study includes participants with CIS NMIBC (± Ta/T1) with active disease, defined as disease present at last tumor evaluation (within 3 months) prior to signing the ICF. Participants will be enrolled into one of 2 cohorts: Cohort A: * Participants with CIS (± Ta/T1) who are BCG naive, or * Participants with CIS (± Ta/T1) who are BCG exposed and have not received intravesical BCG for at least 24 months prior to the most recent CIS diagnosis Cohort B: * Participants who are BCG unresponsive

Conditions

  • Non-muscle Invasive Bladder Cancer

Interventions

  • TARA-002Biological

    All participants will receive 6 weekly instillations of TARA-002 at the established RP2D (First Treatment Period). Participants who are eligible for reinduction after the First Treatment Period will receive 6 additional weekly doses of TARA-002 instillation as part of the Second Treatment Period. Participants confirmed to have a complete response after the First Treatment Period will receive 3 additional weekly doses of TARA-002 instillation as maintenance during the Second Treatment Period. All eligible participants will receive 3 weekly doses of TARA-002 instillation as part of the Third Treatment Period (maintenance) at Months 6, 9, 12, 15, 18 and 24. Following the Third Treatment Period, all participants will continue to the Follow up Period from Month 27 until Month 60.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cohort A and B: Incidence of high-grade Complete Response at any time according to central pathology after treatment with TARA-002Time frame: Month 3 to Month 60

Locations

78 sites in 7 countries. Site status is shown where the registry gives one.

  • Urology Centers of Alabama

    Homewood, Alabama · Recruiting

  • Mayo Clinic

    Phoenix, Arizona · Recruiting

  • East Valley Urology Center of Arizona

    Queen Creek, Arizona · Recruiting

  • Arkansas Urology

    Little Rock, Arkansas · Recruiting

  • Michael Oefelein Clinical Trials

    Bakersfield, California · Recruiting

  • Urology Group of Southern California

    Los Angeles, California · Terminated

  • University of California Irvine Medical Center

    Orange, California · Recruiting

  • Genesis Research

    San Diego, California · Withdrawn

  • Genesis Research LLC

    Torrance, California · Recruiting

  • Colorado University - Anshutz

    Aurora, Colorado · Recruiting

  • AdventHealth Medical Group Urology of Denver

    Denver, Colorado · Recruiting

  • Advanced Urology

    Lakewood, Colorado · Recruiting

  • Urology Associates of Denver

    Lone Tree, Colorado · Recruiting

  • University of Florida Health Jacksonville

    Gainesville, Florida · Withdrawn

  • Mayo Clinic

    Jacksonville, Florida · Recruiting

  • Comprehensive Urologic Care

    Lake Barrington, Illinois · Recruiting

  • Southern Urology

    Lafayette, Louisiana · Recruiting

  • Ochsner Health LSU - Regional Urology

    Shreveport, Louisiana · Withdrawn

  • Brigham and Women's Hospital

    Boston, Massachusetts · Recruiting

  • Greater Boston Urology, LLC

    Plymouth, Massachusetts · Recruiting

  • Minnesota Urology, Woodbury

    Bloomington, Minnesota · Recruiting

  • Mayo Clinic

    Rochester, Minnesota · Recruiting

  • Renown Regional Medical Center

    St Louis, Missouri · Recruiting

  • Specialty Clinic Research of St. Louis

    St Louis, Missouri · Recruiting

  • AccuMed Research Associates

    Garden City, New York · Terminated

  • Laura & Isaac Perlmutter Cancer Center - NYU Langone Health

    New York, New York · Recruiting

  • University of Rochester, Department of Urology

    Rochester, New York · Recruiting

  • Associated Medical Professionals of NY, PLLC

    Syracuse, New York · Recruiting

  • Montefiore Medical Center

    The Bronx, New York · Recruiting

  • Cleveland Clinic Main Campus, Cleveland

    Cleveland, Ohio · Recruiting

  • University of Toledo

    Toledo, Ohio · Withdrawn

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania · Recruiting

  • Carolina Urologic Research Center

    Myrtle Beach, South Carolina · Recruiting

  • Conrad Person Clinic

    Memphis, Tennessee · Recruiting

  • Urology Associates PC

    Nashville, Tennessee · Recruiting

  • Amarillo Urology Research

    Amarillo, Texas · Withdrawn

  • Urology Partners of North Texas

    Arlington, Texas · Recruiting

  • Urology Austin, LLC

    Austin, Texas · Recruiting

  • Houston Metro Urology

    Houston, Texas · Recruiting

  • Houston Methodist Hospital

    Houston, Texas · Recruiting

Showing 40 of 78 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.